Point mutation and homozygous deletion of PTEN/MMAC1 in primary bladder cancers - PubMed (original) (raw)
. 1998 Jun 18;16(24):3215-8.
doi: 10.1038/sj.onc.1201855.
Affiliations
- PMID: 9671402
- DOI: 10.1038/sj.onc.1201855
Point mutation and homozygous deletion of PTEN/MMAC1 in primary bladder cancers
P Cairns et al. Oncogene. 1998.
Abstract
A new tumor suppressor gene PTEN/MMAC1 was recently isolated at chromosome 10q23 and found to be inactivated by point mutation or homozygous deletion in glioma, prostate and breast cancer. PTEN/MMAC1 was also identified as the gene predisposing to Cowden disease, an autosomal dominant cancer predisposition syndrome associated with an increased risk of breast, skin and thyroid tumors and occasional cases of other cancers including bladder and renal cell carcinoma. We screened 345 urinary tract cancers by microsatellite analysis and found chromosome 10q to be deleted in 65 of 285 (23%) bladder and 15 of 60 (25%) renal cell cancers. We then screened the entire PTEN/MMAC1 coding region for mutation in 25 bladder and 15 renal cell primary tumors with deletion of chromosome 10q. Two somatic point mutations, a frameshift and a splicing variant, were found in the panel of bladder tumors while no mutation was observed in the renal cell carcinomas. To screen for homozygous deletion, we isolated two polymorphic microsatellite repeats from genomic BAC clones containing the PTEN/MMAC1 gene. Using these new informative markers, we identified apparent retention at the gene locus indicative of homozygous deletion of PTEN/MMAC1 in four of 65 bladder and 0 of 15 renal cell tumors with LOH through chromosome 10q. Identification of the second inactivation event in six bladder tumors with LOH of 10q implies that the PTEN/MMAC1 gene is occasionally involved in bladder tumorigenesis. However, the low frequency of biallelic inactivation suggests that either PTEN/MMAC1 is inactivated by other mechanisms or it is not the only target of chromosome 10q deletion in primary bladder and renal cell cancer.
Similar articles
- MMAC1/PTEN mutations in primary tumor specimens and tumor cell lines.
Teng DH, Hu R, Lin H, Davis T, Iliev D, Frye C, Swedlund B, Hansen KL, Vinson VL, Gumpper KL, Ellis L, El-Naggar A, Frazier M, Jasser S, Langford LA, Lee J, Mills GB, Pershouse MA, Pollack RE, Tornos C, Troncoso P, Yung WK, Fujii G, Berson A, Steck PA, et al. Teng DH, et al. Cancer Res. 1997 Dec 1;57(23):5221-5. Cancer Res. 1997. PMID: 9393738 - Somatic mutation and homozygous deletion of PTEN/MMAC1 gene of 10q23 in renal cell carcinoma.
Alimov A, Li C, Gizatullin R, Fredriksson V, Sundelin B, Klein G, Zabarovsky E, Bergerheim U. Alimov A, et al. Anticancer Res. 1999 Sep-Oct;19(5B):3841-6. Anticancer Res. 1999. PMID: 10628321 - Mutation analysis of the putative tumor suppressor gene PTEN/MMAC1 in primary breast carcinomas.
Rhei E, Kang L, Bogomolniy F, Federici MG, Borgen PI, Boyd J. Rhei E, et al. Cancer Res. 1997 Sep 1;57(17):3657-9. Cancer Res. 1997. PMID: 9288766 - Mutational spectra of PTEN/MMAC1 gene: a tumor suppressor with lipid phosphatase activity.
Ali IU, Schriml LM, Dean M. Ali IU, et al. J Natl Cancer Inst. 1999 Nov 17;91(22):1922-32. doi: 10.1093/jnci/91.22.1922. J Natl Cancer Inst. 1999. PMID: 10564676 Review. - [Cowden disease].
Sawada T, Hamano N, Suzuki A, Okada T, Mabuchi H. Sawada T, et al. Nihon Rinsho. 2000 Jul;58(7):1479-83. Nihon Rinsho. 2000. PMID: 10921327 Review. Japanese.
Cited by
- CSTP1, a novel protein phosphatase, blocks cell cycle, promotes cell apoptosis, and suppresses tumor growth of bladder cancer by directly dephosphorylating Akt at Ser473 site.
Zhuo DX, Zhang XW, Jin B, Zhang Z, Xie BS, Wu CL, Gong K, Mao ZB. Zhuo DX, et al. PLoS One. 2013 Jun 17;8(6):e65679. doi: 10.1371/journal.pone.0065679. Print 2013. PLoS One. 2013. PMID: 23799035 Free PMC article. - Structural or functional defects of PTEN in urothelial cells lacking P53 drive basal/squamous-subtype muscle-invasive bladder cancer.
He F, Zhang F, Liao Y, Tang MS, Wu XR. He F, et al. Cancer Lett. 2022 Dec 1;550:215924. doi: 10.1016/j.canlet.2022.215924. Epub 2022 Oct 3. Cancer Lett. 2022. PMID: 36195293 Free PMC article. - Hypermethylation of FOXA1 and allelic loss of PTEN drive squamous differentiation and promote heterogeneity in bladder cancer.
Osei-Amponsa V, Buckwalter JM, Shuman L, Zheng Z, Yamashita H, Walter V, Wildermuth T, Ellis-Mohl J, Liu C, Warrick JI, Shantz LM, Feehan RP, Al-Ahmadie H, Mendelsohn C, Raman JD, Kaestner KH, Wu XR, DeGraff DJ. Osei-Amponsa V, et al. Oncogene. 2020 Feb;39(6):1302-1317. doi: 10.1038/s41388-019-1063-4. Epub 2019 Oct 21. Oncogene. 2020. PMID: 31636388 - Allelic loss of 10q23, the PTEN tumour suppressor gene locus, in Barrett's oesophagus-associated adenocarcinoma.
Kulke MH, Odze RD, Thakore KS, Thomas G, Wang H, Loda M, Eng C. Kulke MH, et al. Br J Cancer. 2001 Mar 23;84(6):748-53. doi: 10.1054/bjoc.2000.1660. Br J Cancer. 2001. PMID: 11259087 Free PMC article. - What we could do now: molecular pathology of bladder cancer.
Knowles MA. Knowles MA. Mol Pathol. 2001 Aug;54(4):215-21. doi: 10.1136/mp.54.4.215. Mol Pathol. 2001. PMID: 11477133 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials